Humacyte, Inc.
NASDAQ:HUMABiotechnology
-$0.03 today
- Market cap
- $138.90M
- Beta
- 2.46
- P/E (TTM)
- -1.9
- EPS (TTM)
- -$0.49
Volume 3.91M
Average 8.14M
HUMA Net Income
Bottom-line profit after all expenses, interest, and taxes.
Humacyte, Inc.NASDAQ: HUMA
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income turns negative
Q1 FY2026 net income was -$17.62M, compared with $39.14M a year earlier. Trailing-twelve-month net income was -$97.59M.
Context
- Net income amounted to 2003.6% of revenue in FY2025.
- Net income grew in size in 2 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 4 analysts of -$91.99M (-125.3%) for the fiscal year ending Dec 2026, a slowdown from the +72.5% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$17.62M+29.0% QoQ
- Last fiscal yearDec 2025
- -$40.83M+72.5% YoY
- LTMMar 2026
- -$97.59M-25.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -145.0% | +16.3% | +161.3 pp |
| 1 year | +72.5% | -125.3% | -197.8 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the income statement
- Latest · FY2025
- (40.83M) USD
- Year-over-year change
- +72.5%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (40.83M) | +72.5% |
| FY2024 | 2024-12-31 | (148.7M) | -34.2% |
| FY2023 | 2023-12-31 | (110.78M) | -825.8% |
| FY2022 | 2022-12-31 | (11.97M) | +54.8% |
| FY2021 | 2021-12-31 | (26.48M) | — |
Net Income vs competitors
How HUMA compares with its peers on the latest reported figures
- HUMA's LTM Mar 2026 net income of -$97.59M is the 7th highest of the 11 companies compared; the peer median is -$77M.
- Its year-over-year change of -25.7% is the 8th highest of 11, against a peer median of -14.0%.
- Net income amounts to 4840.8% of revenue for HUMA, versus a peer median of 266.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
SGMTSagimet Biosciences Inc. | LTM Mar 2026 | -$43.51M | +23.8% | — | — |
| LTM Mar 2026 | -$51.99M | -12.6% | — | — | |
| LTM Mar 2026 | -$54.44M | +11.9% | — | — | |
| LTM Mar 2026 | -$57.09M | +16.9% | — | — | |
| LTM Mar 2026 | -$75.32M | +6.4% | — | 266.9% | |
| LTM Mar 2026 | -$78.67M | -15.4% | — | 173.5% | |
| LTM Mar 2026 | -$97.59M | -25.7% | — | 4840.8% | |
| LTM Mar 2026 | -$116.64M | -37.7% | — | 319.6% | |
| LTM Mar 2026 | -$166.12M | -770.3% | — | 2895.1% | |
| LTM Mar 2026 | -$169.52M | -21.5% | — | — | |
| LTM Mar 2026 | -$239.55M | -441.4% | — | 110.0% | |
| Peer median (excluding HUMA) | -$77M | -14.0% | — | 266.9% | |
Competitors are the stored peer set for HUMA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.26M | 1.57M | 0 | 0 | 2.04M |
| Cost of Revenue | 61.34M | 8.26M | 76.55M | 7.19M | 17.05M |
| Gross Profit | (60.08M) | (6.69M) | (76.55M) | (7.19M) | (15.01M) |
| Gross Margin | -4756.8% | -427.5% | — | — | -736.5% |
| Research & Development | 61.34M | 63.26M | 76.55M | 88.6M | 69.3M |
| Selling, General & Admin | 21.13M | 22.88M | 20.39M | 25.8M | 31.17M |
| Operating Expenses | 21.13M | 77.89M | 23.5M | 107.21M | 92.43M |
| Depreciation & Amortization | 8.24M | 8.21M | 7.72M | 7.19M | 7.35M |
| EBITDA | (13.89M) | 2.45M | (96.46M) | (132.23M) | (22.24M) |
| EBITDA Margin | -1099.6% | 156.2% | — | — | -1091.2% |
| Operating Income | (81.21M) | (84.58M) | (100.05M) | (114.4M) | (107.44M) |
| Operating Margin | -6429.8% | -5404.3% | — | — | -5271.7% |
| Interest Income | 16K | 2.63M | 5.47M | 4.1M | 2.59M |
| Interest Expense | 4.35M | 6.2M | 6.6M | 9.28M | 11.25M |
| Other Income / Expenses | 54.73M | 72.61M | (10.73M) | (34.3M) | 66.6M |
| Income Before Tax | (26.48M) | (11.97M) | (110.78M) | (148.7M) | (40.83M) |
| Pre-Tax Margin | -2096.4% | -764.5% | — | — | -2003.6% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (26.48M) | (11.97M) | (110.78M) | (148.7M) | (40.83M) |
| Net Margin | -2096.4% | -764.5% | — | — | -2003.6% |
| EPS (Basic) | (0.66) | (0.12) | (1.07) | (1.26) | (0.26) |
| EPS (Diluted) | (0.66) | (0.12) | (1.07) | (1.26) | (0.26) |
| Weighted Avg Shares | 39.97M | 103.05M | 103.42M | 118.48M | 158.16M |
| Weighted Avg Shares (Diluted) | 39.97M | 103.05M | 103.42M | 118.48M | 158.16M |
Humacyte, Inc.
NASDAQ:HUMA
Intrinsic Alpha fair value
Locked
Current Price
$0.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.